EZH2 and neoplasm: To circumvent this issue, a majority of investigators have focused on synthetic lethality approaches aimed to illuminate which tumor (sub)types harboring inactivating mutations in other epigenetic genes such as KDM6 are highly sensitive to EZH2 inhibition.